IL-17 inhibitors
Immunology· 4 reviewed drugs· 10483 cited findings behind them
What the regulatory reviews cover
The IL-17 inhibitors reviewed in this library include Bimzelx, Cosentyx, Taltz, and Kyntheum. These drugs have been reviewed for indications such as moderate to severe plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
Regulatory reviews report various efficacy measures. For instance, Bimzelx showed a PASI 90 response rate of 90.8% compared to 4.8% for placebo. Cosentyx demonstrated a PASI 75 response of 95%. Taltz achieved a PASI-75 response rate of 90%. Kyntheum reported 82.5% PASI 75 responders. It is important to note that different drugs were studied in different trials, and therefore, the reported figures are not directly comparable head-to-head.
The drugs — one cited result each
| Bimzelx UCB SA | PASI 90 response rate: 90.8 UCB S A — Bimzelx EMA EPAR public assessment report (EMEA/H/, p.214 |
| Cosentyx Novartis AG | PASI 75 response: 95 NOVARTIS PHARMS CORP — Cosentyx FDA Review (NDA/BLA 125504,, p.26 |
| Taltz Eli Lilly and Company | PASI-75 response rate: 90% Eli Lilly and Company — Taltz FDA Review (BLA125521, ORIG 1,, p.109 |
| Kyntheum LEO A S | PASI 75 responders (%): 82.5 LEO A S — Kyntheum EMA EPAR public assessment report (EMEA/H, p.39 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Immunology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.